NASDAQ:NTRA - Natera Stock Price, Forecast & News

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera Inc (NASDAQ:NTRA) issued its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.20. The medical research company had revenue of $77.90 million for the quarter, compared to the consensus estimate of $73.97 million. Natera had a negative return on equity of 252.79% and a negative net margin of 42.45%. The firm's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.49) earnings per share. View Natera's Earnings History.

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Natera.

5 analysts have issued 1 year price targets for Natera's shares. Their forecasts range from $32.00 to $49.00. On average, they expect Natera's share price to reach $42.40 in the next year. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Natera.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

News coverage about NTRA stock has trended neutral recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natera earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Natera.

Natera saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,990,000 shares, an increase of 9.6% from the January 15th total of 3,640,000 shares. Based on an average trading volume of 692,500 shares, the days-to-cover ratio is presently 5.8 days. Currently, 5.9% of the company's stock are sold short. View Natera's Current Options Chain.

Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC) and Psychemedics (PMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.79%), FMR LLC (4.76%), Jennison Associates LLC (3.27%), State Street Corp (3.21%), Bridger Management LLC (1.62%) and Credit Suisse AG (1.26%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Driehaus Capital Management LLC, UBS Group AG, PNC Financial Services Group Inc., AXA, Bank of New York Mellon Corp, Rafferty Asset Management LLC and Perkins Capital Management Inc.. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Bridger Management LLC, State Street Corp, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Columbus Circle Investors, Parkman Healthcare Partners LLC, Madison Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Natera.

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRA stock can currently be purchased for approximately $37.13.

Natera has a market capitalization of $2.88 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

The official website for Natera is http://www.natera.com/.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]